Can bringing HIV prevention to communities beat clinic visits?

NCT ID NCT06176859

Completed Prevention Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study compares two ways to provide HIV prevention pills (PrEP) to young people in South Africa: the usual clinic-based approach versus a community-based model where pills are delivered and monitored outside clinics. Researchers will enroll 2,500 participants aged 16-30 to see which method leads to more people starting and staying on PrEP over 12 months. The goal is to find a safer, more effective way to expand access to HIV prevention.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pre-exposure prophylaxis (PrEP) for HIV prevention
What this could lead to: If successful, this could make PrEP more accessible and convenient for young people in South Africa, reducing new HIV infections.
What could go wrong: This is a large but early-stage implementation study; results may not apply to other regions or populations. Community-based delivery may face logistical challenges.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ART are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS Arts syndrome HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ART HIV HUMAN IMMUNODEFICIENCY VIRUS

Contacts and locations

Locations

Human Sciences Research Council

Durban, KwaZulu-Natal, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.